News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
《藍籌》中生製藥(01177.HK)全年純利跌33% 基本溢利增31.4% 末期息5港仙
中國生物製藥(01177.HK)公布2025年度業績，收入318.34億人民幣(下同)，按年升10.3%。股東應佔溢利23.43億元，按年跌33%；每股盈利13.02分。派末期息5港仙，上年同期派4港仙。連同已派發中期股息每股5港仙，全年合共派發股息每股10港仙。若撇除已終止經營業務、若干非現金項目及聯營公司影響，基本溢利45.41億元，按年升31.4%。創...
Reset
Send
The window will close in 5 seconds
《藍籌》中生製藥(01177.HK)全年純利跌33% 基本溢利增31.4% 末期息5港仙
Close
Recommend
18
Positive
28
Negative
21
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

中國生物製藥(01177.HK)  -0.030 (-0.472%)    Short selling $142.91M; Ratio 75.915%   公布2025年度業績，收入318.34億人民幣(下同)，按年升10.3%。股東應佔溢利23.43億元，按年跌33%；每股盈利13.02分。派末期息5港仙，上年同期派4港仙。連同已派發中期股息每股5港仙，全年合共派發股息每股10港仙。

Dividend History
Announce DateEventParticular
2025/08/18InterimD:HKD 0.0500
2025/03/20FinalD:HKD 0.0400 (Equivalent to approximately RMB 0.0376)
2024/08/13InterimD:HKD 0.0300
2024/03/28FinalD:HKD 0.0300

若撇除已終止經營業務、若干非現金項目及聯營公司影響，基本溢利45.41億元，按年升31.4%。創新產品收入152.2億元，升26.2%，佔總收入比例升至47.8%。研發總投入63.17億元，佔收入19.8%。(ec/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-02 16:25.)
AASTOCKS新聞

Switch to Auto-Translated Version
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.